このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

原発性膜性腎症に対するベリムマブとリツキシマブ (REBOOT)

原発性膜性腎症の治療におけるベリムマブとリツキシマブの有効性をリツキシマブ単独と比較 (ITN080AI)

The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.

Background:

Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.

Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.

Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.

In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.

Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.

調査の概要

詳細な説明

This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy (MN), ages 18-75 inclusive. The study will be conducted at multiple sites in the United States and Canada.

Part A: Open-label Phase

Part A is an open-label, PK study to compare belimumab exposure between participants who have "low" proteinuria (≥ 4 to < 8 g/day) and "high" proteinuria (≥ 8 g/day) at Visit -1.

Initially Part A planned to enroll 20 individuals with primary MN: 10 individuals with low proteinuria and 10 individuals with high proteinuria. All Part A participants received 200 mg subcutaneous belimumab weekly, the initially approved dose of belimumab in SLE, for 52 doses (weeks 0-51). Trough serum belimumab levels would be obtained weekly following the first 4 doses of belimumab. All participants would receive rituximab 1000 mg IV at weeks 4 and 6, and are followed after the 52 week treatment period on no study medication until week 156.

Belimumab trough levels were to be analyzed after all 20 participants received the first 4 doses to compare the belimumab exposure between the low and high proteinuria groups. If the belimumab exposure was not comparable between the high and low proteinuria groups, the belimumab dose would be doubled to 400 mg/weekly for participants with high proteinuria in Part B. Dose determination for participants with high proteinuria in Part B would be made by an adjudication committee comprised of the Protocol Chair, NIAID Medical Monitor, ITN Clinical Trial Physician, and Rho Scientist, in consultation with the belimumab PK expert at GSK.

Due in part to the observed imbalance in enrollment between the high and low proteinuria groups, an ad hoc PK analysis was conducted. The serum belimumab trough levels of the first 12 participants (8 with high proteinuria and 4 with low proteinuria) who received the first 4 belimumab doses were analyzed to compare belimumab exposure between the low and high proteinuria groups.

The results of the PK analysis were reviewed by the adjudication committee, who determined that the results did not support doubling the dose of belimumab in individuals with high proteinuria nor did it identify a new proteinuria threshold that warranted an increased belimumab dose. The belimumab PK expert at GSK concurred. Thus, enrollment into Part A has been suspended, and all participants in Part B are to receive the same dose of belimumab. All participants currently enrolled in Part A continue to receive belimumab and rituximab as previously planned and are undergoing the safety assessments as presented in Appendix A.

All enrolled participants in Part A will be followed until week 156 and will be assessed for the same study endpoints as participants in Part B.

Part B: Randomized Phase

Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN to assess the effectiveness of belimumab and rituximab at treating primary MN. Part B is commencing after the completion of the ad hoc PK analysis, which did not support increasing the belimumab dose in participants with high proteinuria.

A total of 58 participants will be randomized into two treatment arms.

Randomization will be stratified by low (≥ 4 to < 8 g/day) and high proteinuria (≥ 8 g/day). Eleven participants who entered Part B prior to protocol version 7.0 were randomized at a 1:1 ratio; 47 participants entering at or after protocol version 7.0 will be randomized at a 3:1 ratio. A total of 41 participants are projected to be enrolled in the belimumab and rituximab arm and 17 participants in the belimumab placebo and rituximab arm. The effectiveness of belimumab with rituximab will be evaluated using a hybrid control arm that combines participants who receive belimumab placebo and rituximab in this study and the subgroup of subjects with primary MN in the MENTOR trial who were anti-PLA2R positive at baseline and received rituximab alone. The randomized arms will also be used to evaluate the safety of adding belimumab to rituximab in primary MN and to support mechanistic studies.

Participants randomized to the belimumab and rituximab arm will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. This dosing regimen is based on the recommended dosing of subcutaneous belimumab for lupus nephritis. Participants randomized to the belimumab placebo and rituximab arm will receive subcutaneous belimumab placebo according to the same dose and schedule.

Participants in both arms will receive rituximab 1000 mg IV at weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and, defined as fulfilling at least two of the following three criteria at week 30, will receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

  • Anti-PLA2R levels is ≥ 25% of baseline
  • Proteinuria is ≥ 50% of baseline
  • Serum albumin is < 2.8 g/dL

After the 52 week treatment period, all participants will be followed on no study medication with assessment of the primary endpoint (CR or PR) at week 104.

The primary endpoint will be assessed at week 104 because the proteinuric response to treatment is known to lag behind the active treatment period and is recommended to be assessed at least 18 months after the initiation of therapy. There will be a tolerance endpoint at week 156 to determine if treatment with belimumab with rituximab results in a more durable remission compared to rituximab alone, and to assess the rate of relapse after having achieved complete or partial remission.

研究の種類

介入

入学 (推定)

58

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35294
        • 募集
        • University of Alabama at Birmingham School of Medicine: Division of Nephrology
        • 主任研究者:
          • Dana Rizk
        • コンタクト:
    • Arkansas
      • Little Rock、Arkansas、アメリカ、72205
        • 募集
        • University of Arkansas
        • コンタクト:
        • 主任研究者:
          • Srilakshmi Ravula
    • California
      • San Francisco、California、アメリカ、94146
        • 募集
        • University of California San Francisco
        • コンタクト:
        • 主任研究者:
          • Raymond Hsu
      • Stanford、California、アメリカ、94305
        • 募集
        • Stanford University School of Medicine: Division of Nephrology
        • 主任研究者:
          • Fahmeedah Kamal
        • コンタクト:
        • コンタクト:
      • Torrance、California、アメリカ、90502
        • 募集
        • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension
        • コンタクト:
        • 主任研究者:
          • Sharon G. Adler
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • University of Colorado
        • 主任研究者:
          • Amber Podoll, MD
        • コンタクト:
    • Florida
      • Jacksonville、Florida、アメリカ、32224
        • 募集
        • Mayo Clinic Jacksonville: Department of Nephrology and Hypertension
        • 主任研究者:
          • Nabeel Aslam
        • コンタクト:
      • Miami、Florida、アメリカ、33136
        • 募集
        • University of Miami Miller School of Medicine, Div of Nephrology
        • 主任研究者:
          • Jair Munoz Mendoza
        • コンタクト:
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • 募集
        • Johns Hopkins
        • 主任研究者:
          • Duvuru Geetha
        • コンタクト:
          • Kristin Lyman
          • 電話番号:(734) 276-1248
          • メール:klyman1@jh.edu
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
        • 主任研究者:
          • Meryl A. Waldman
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48104
        • 募集
        • University of Michigan
        • 主任研究者:
          • Andrea Oliverio
        • コンタクト:
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • University of Minnesota Health Clinical Research Unit
        • コンタクト:
        • 主任研究者:
          • Patrick H. Nachman
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • 募集
        • Washington University in St. Louis
        • 主任研究者:
          • Tinting Li
        • コンタクト:
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • 募集
        • University of Nebraska
        • 主任研究者:
          • Prasanth Ravipati
        • コンタクト:
    • New York
      • New York、New York、アメリカ、10032
        • 募集
        • Columbia University Medical Center: Division of Nephrology
        • コンタクト:
        • 主任研究者:
          • Andrew S. Bomback
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27599-
        • 募集
        • University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center
        • コンタクト:
        • 主任研究者:
          • Vimal K. Derebail
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • 募集
        • Cleveland Clinic
        • 主任研究者:
          • John Sedor
        • コンタクト:
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • Ohio State University Wexner Medical Center: Division of Nephrology
        • コンタクト:
        • 主任研究者:
          • Isabelle Ayoub
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division
        • コンタクト:
        • 主任研究者:
          • Gaia Coppock
    • Washington
      • Spokane、Washington、アメリカ、99204
        • 募集
        • Providence Medical Research Center, Providence Health Care: Nephrology
        • コンタクト:
        • 主任研究者:
          • Katherine R. Tuttle

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for this study-

  1. Age 18 to 75 years inclusive

  2. Diagnosis of one of the following:

    1. Primary MN confirmed by a kidney biopsy within the past 5 years
    2. Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years
    3. Nephrotic syndrome with eGFR > 60 mL/min/1.73m2 and no history of immunosuppressant treatment (e.g. glucocorticoids, cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting agent) for nephrotic syndrome, and without evidence of a secondary cause of nephrotic syndrome
    4. Nephrotic syndrome and a contraindication to kidney biopsy (e.g., anticoagulation, solitary kidney, body habitus that increases the risk of biopsy, or other contraindication in the opinion of the investigator), and without evidence of a secondary cause of nephrotic syndrome
  3. Serum anti-PLA2R positive

  4. eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade

  5. Proteinuria:

    1. ≥ 4 and < 8 g/day that has persisted for at least the previous 3 months while on maximally tolerated RAS blockade. Documentation of persistent proteinuria may be from a 24-hour collection or calculated from a spot urine collection. Or,
    2. ≥ 8 g/day while on maximally tolerated RAS blockade
  6. Blood pressure while on maximally tolerated RAS blockade:

    1. Systolic blood pressure ≤ 140 mmHg
    2. Diastolic blood pressure ≤ 90 mmHg

Exclusion Criteria:

Subjects meeting any of the following criteria will not be eligible for this study-

  1. Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation

  2. Rituximab use within the previous 12 months

  3. Rituximab use > 12 months ago:

    1. With an undetectable CD19 B cell count, or
    2. Did not result in a CR (Section 3.3.1) or PR (Section 3.3.2) with rituximab treatment alone (e.g., without other immunosuppressive or immunomodulatory therapy)
  4. Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)

  5. Cyclophosphamide use within the past 3 months

  6. Use of other immunosuppressive medications such as cyclosporine or tacrolimus within the past 30 days

  7. Use of systemic corticosteroids within the past 30 days

  8. Use of any biologic investigational agent (defined as any drug not approved for sale in the country it is used) in the previous 12 months

  9. Use of any non-biologic investigational agent in the past 30 days (or 5 half-lives, whichever is greater)

  10. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 9.0%

  11. Patients with diabetic glomerulopathy on renal biopsy that is:

    1. Greater than Class I diabetic glomerulopathy, or
    2. Class I diabetic glomerulopathy with a history of poor diabetic control (e.g., HbA1c ≥ 9.0%) since time of biopsy
  12. Unstable kidney function defined as > 20% decrease in eGFR during the previous 3 months due to primary MN, as determined by the site investigator in consultation with the protocol chair

  13. Decrease in proteinuria by 50% or more during the previous 12 months

  14. WBC count < 3.0 x 103/μl

  15. Absolute neutrophil count < 1.5 x 103/μl

  16. Moderately severe anemia (hemoglobin < 9 g/dL)

  17. History of primary immunodeficiency

  18. Serum IgA < 10 mg/dL

  19. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)

  20. Positive HIV serology

  21. Positive HCV serology, unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy)

  22. Evidence of current or prior infection with hepatitis B, as indicated by positive HBsAg or positive HBcAb

  23. Positive QuantiFERON - TB Gold test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold test

  24. History of lung disease with FVC < 70% predicted, DLCO < 70% predicted, or requiring supplemental oxygen

  25. History of malignant neoplasm within the last 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years

  26. Absence of individualized, age-appropriate cancer screening

  27. Women of child-bearing potential who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception until week 104

  28. Acute or chronic infection, including current use of suppressive therapy for chronic infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection

  29. History of an anaphylactic reaction or known sensitivity or intolerance to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies, including rituximab or belimumab

  30. Evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk

  31. Evidence of current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence in the past 12 months

  32. Vaccination with a live vaccine within the past 30 days

  33. Other diseases or conditions or other clinically significant abnormal laboratory value which in the opinion of the investigator would put the patient at risk or confound the results of the study

  34. Inability to comply with study and follow-up procedures

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part A: Low Proteinuria Group - Belimumab and Rituximab

Open-label pharmacokinetics (PK) phase.

Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.

Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day).

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

他の名前:
  • ベンリスタ®

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

他の名前:
  • リツキサン®
実験的:Part A :High Proteinuria Group - Belimumab and Rituximab

Open-label pharmacokinetics (PK) phase.

Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.

High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day).

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

他の名前:
  • ベンリスタ®

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

他の名前:
  • リツキサン®
実験的:Part B: Belimumab and Rituximab

Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

  • Anti-PLA2R level is ≥ 25% of baseline
  • Proteinuria is ≥ 50% of baseline
  • Serum albumin is < 2.8 g/dL

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

他の名前:
  • ベンリスタ®

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

他の名前:
  • リツキサン®
プラセボコンパレーター:Part B: Placebo and Rituximab

Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

  • Anti-PLA2R level is ≥ 25% of baseline
  • Proteinuria is ≥ 50% of baseline
  • Serum albumin is < 2.8 g/dL

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

他の名前:
  • リツキサン®

The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Standard weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

他の名前:
  • ベリムマブ プラセボ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104.
時間枠:Week 104

. CR is defined as proteinuria of ≤ 0.3 g/day with a serum albumin ≥ 3.5 g/dL. PR is defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria < 3.5 g/day glomerular filtration rate (eGFR) from baseline.

Week 104

二次結果の測定

結果測定
メジャーの説明
時間枠
30週目にリツキシマブの2回目のコースの基準を満たす参加者の割合
時間枠:30週目
30週目
52週目および156週目で完全寛解または部分寛解(CRまたはPR)となった参加者の割合。
時間枠:第52週、第156週
第52週、第156週
52週目、104週目、156週目に完全寛解(CR)となった参加者の割合。
時間枠:52週目、104週目、156週目
52週目、104週目、156週目
52週目、104週目、156週目におけるPRには参加したがCRには参加しなかった参加者の割合。
時間枠:52週目、104週目、156週目
52週目、104週目、156週目
CR または PR を達成した参加者の再発までの時間。
時間枠:最大156週間(3年間)
最大156週間(3年間)
52週目、104週目、156週目のタンパク尿レベル。
時間枠:52週目、104週目、156週目
52週目、104週目、156週目
52週目、104週目、および156週目でCRまたはPRおよび抗PLA2R陰性となった参加者の割合
時間枠:52週目、104週目、156週目
52週目、104週目、156週目
52、104、156週目にPR陰性および抗PLA2R陰性となった参加者の割合
時間枠:52週目、104週目、156週目
52週目、104週目、156週目
PR ではなく CR ではなく、52 週目、104 週目、および 156 週目に抗 PLA2R 陰性である参加者の割合
時間枠:第52週、第104週、第156週
第52週、第104週、第156週
52、104、156週目に抗PLA2R陰性となった参加者の割合
時間枠:第52週、第104週、第156週
第52週、第104週、第156週
52週目、104週目、156週目の生活の質
時間枠:第52週、第104週、第156週
第52週、第104週、第156週
有害事象 (AE) の発生率。
時間枠:第0週目から第52週目まで
第0週目から第52週目まで
Incidence of Grade 3 or Higher Infectious Adverse Events (AEs): By Treatment Group
時間枠:Week 0 to Week 52

Reference: NCI-CTCAE manual titled, National Cancer Institute (NCI)s Common Terminology Criteria for Adverse Events Version 5.0 (published November 27, 2017).

Week 0 to Week 52
Incidence of Arterial Thromboembolic Events: By Treatment Group
時間枠:Week 0 to Week 52

Peripheral vascular embolism, mesenteric infarct, or myocardial infarction.

Week 0 to Week 52
Incidence of Venous Thromboembolic Events: By Treatment Group
時間枠:Week 0 to Week 52

Venous thromboembolic event (VTE) is defined as a symptomatic deep vein thrombosis (DVT): the formation of a blood clot in a deep vein, detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism (PE). An embolism is a clot in the blood that forms and blocks a blood vessel. A pulmonary embolism is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches.

Week 0 to Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディチェア:Patrick Nachman、University of Minnesota, Department of Medicine, Division of Renal Diseases and Hypertension
  • スタディチェア:Iñaki Sanz、Emory University, Department of Medicine, Division of Rheumatology

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年3月6日

一次修了 (推定)

2029年3月1日

研究の完了 (推定)

2030年3月1日

試験登録日

最初に提出

2019年5月13日

QC基準を満たした最初の提出物

2019年5月13日

最初の投稿 (実際)

2019年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

IPD 共有時間枠

On average, within 24 months after database lock for the trial.

IPD 共有アクセス基準

Open access.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する